drugset
drugset / Trial / NCT04844970

Anamorelin Study for Advanced Pancreatic Cancer

NCT04844970 ↗

Phase 2 Terminated 4 enrolled Lahey Clinic Helsinn Healthcare SA · collabQuartesian LLC · collab
RandomizedParallel-groupDouble-blindSupportive care

Summary

Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day

Timeline

Start
2023-04-01
Primary completion
2023-11-07
Completion
2023-11-07

Outcome

Outcome not reported

Stopped (Enrollment): “The study closure was initiated by the financial sponsor and agreed upon by the site PI. The study is closing because of low enrollment and insufficient funds.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Anamorelin Small molecule 100 mg Oral

Indications

pancreatic ductal adenocarcinoma